Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70.CAR NK Cells in DLBCL and Hodgkin Lymphoma
NCT07164469Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2026
- Primary completion
- Sep 2031
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR.70/IL15-transduced CB-NK cells in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CAR.70/IL15-transduced CB-NK cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT07164469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164469.